Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

In a less buoyant market environment for furnishings and with high comparison base in 2023 (year at a record) , Roche Bobois SA reports resilient annual results in line with expectations.

Roche (RHHBY) announced that the European Commission, EC, has approved Columvi in combination with gemcitabine and oxaliplatin for the ...

AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new US filing could extend its use into the first-line setting. Roche has ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Roche RHHBY announced that the European Commission has approved its lymphoma drug, Columvi (glofitamab), for second-line ...